Longitudinally Profiling Neutralizing Antibody Response to SARS Coronavirus with Pseudotypes

Details

• Alternative Title:
  Emerg Infect Dis
• Personal Author:
  Temperton, Nigel J. ; Chan, Paul K. ; Simmons, Graham ; Zambon, Maria C. ; Tedder, Richard S. ; Takeuchi, Yasuhiro ; Weiss, Robin A.
• Description:
  The severe acute respiratory syndrome-associated coronavirus (SARS-CoV) spike protein (S) is a major target for neutralizing antibodies. Retroviral SARS-CoV S pseudotypes have been constructed and used to develop an in vitro microneutralization assay that is both sensitive and specific for SARS-CoV neutralizing antibodies. Neutralization titers measured by this assay are highly correlated to those measured by an assay using replication-competent SARS-CoV. No cross-neutralization occurred with human sera known to contain antibodies to coronavirus strains OC43 and 229E. The pseudotype assay was used to profile neutralizing antibody responses against SARS-CoV S in sequential serum samples taken from 41 confirmed SARS patients during the 2003 outbreak in Hong Kong and shows long-lasting immunity in most recovered patients. The pseudotype assay does not require handling live SARS virus; it is a useful tool to determine neutralizing titers during natural infection and the preclinical evaluation of candidate vaccines.
• Subjects:
  • Research
  • SARS virus
  • Neutralization tests
  • Infectious diseases
  • emerging
  • Vaccines
  • research
  • Adolescent
  • Adult
  • Aged
  More +
• Source:
  Emerg Infect Dis. 11(3):411-416.
• Document Type:
  Journal Article
• Volume:
  11
• Issue:
  3
• Download URL:
  https://stacks.cdc.gov/view/cdc/15710/cdc_15710_DS1.pdf
• File Type:
  [PDF - 203.46 KB]
• Collection(s):
  Emerging Infectious Diseases
• Main Document Checksum:
  urn:sha256:a5d1d2c8560195450d9fd7e30bf64502309696451849c08834b7ad605533bb0b